Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Precision Biosciences Inc
(NQ:
DTIL
)
10.46
-0.04 (-0.33%)
Streaming Delayed Price
Updated: 1:30 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Precision Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
September 09, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
September 09, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
September 02, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's...
Via
Benzinga
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
September 02, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...
Via
Benzinga
Exposures
COVID-19
Product Safety
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
August 25, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
Precision BioSciences: Q2 Earnings Insights
August 12, 2021
Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year...
Via
Benzinga
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
August 05, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy
July 01, 2021
Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin...
Via
Benzinga
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
July 01, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
60 Biggest Movers From Yesterday
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
June 28, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision...
Via
Benzinga
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
June 28, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
24 Stocks Moving in Monday's Pre-Market Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...
Via
Benzinga
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
June 04, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
June 01, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
May 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...
Via
Benzinga
Exposures
COVID-19
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
May 27, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021
From
Precision BioSciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
May 20, 2021
Gainers Enveric Biosciences (NASDAQ:ENVB)...
Via
Benzinga
Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
May 20, 2021
Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
May 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting
May 19, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
Recap: Precision BioSciences Q1 Earnings
May 13, 2021
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($...
Via
Benzinga
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update
May 13, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.